Juventas Therapeutics

Latest Headlines

Latest Headlines

Regenerative push grows as Green Cross, POSCO Capital buy stake in U.S.-based Juventas

South Korea's Green Cross Holdings and POSCO Capital joined to buy a $7.5 million stake in U.S.-based Juventas Therapeutics, pushing a regenerative and biologics growth strategy that has seen recent deals in China and Russia.

Juventas snaps up business development veteran

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Juventas snags $22M B round for mid-stage stem cell program

More than a year after flagging its interest in a B round, Cleveland Clinic-spinout Juventas Therapeutics has put the final pieces together for a $22.2 million raise.

Juventas plans $25M venture round in wake of PhI success

The CEO of Juventas Therapeutics, a spinoff of the Cleveland Clinic, says that now that the company has wrapped a successful Phase I trial of its lead stem cell therapy, it plans to raise $25 million